Dasatinib, also known as BMS-354825, is a cancer drug produced by Bristol-Myers Squibb and sold under the trade name Sprycel. Dasatinib is an oral dual BCR/ABL and Src family tyrosine kinases inhibitor approved for use in patients with chronic myelogenous leukemia (CML) after imatinib treatment and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It is also being assessed for use in metastatic melanoma.
Related Substances (HPLC):
Any single impurity:
(same/less than)0.5%
Total Impurities:
(same/less than)1.0%
Solubility:
Insoluble in water and slightly soluble in ethanol and methanol
Method for Determining Identity:
Proton NMR Spectroscopic Analysis, HPLC
Loss on Drying: (same/less than) 0.5%
Residue on ignition: (same/less than) 0.2%
Heavy Metals: (same/less than) 0.002%